ALX Oncology Holdings Inc. (ALXO)
NASDAQ: ALXO · IEX Real-Time Price · USD
6.15
-0.46 (-6.96%)
At close: Jul 19, 2024, 4:00 PM
6.37
+0.22 (3.58%)
Pre-market: Jul 22, 2024, 9:00 AM EDT
ALX Oncology Holdings Employees
ALX Oncology Holdings had 72 employees as of December 31, 2023. The number of employees increased by 14 or 24.14% compared to the previous year.
Employees
72
Change (1Y)
14
Growth (1Y)
24.14%
Revenue / Employee
n/a
Profits / Employee
-$2,308,361
Market Cap
320.42M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 72 | 14 | 24.14% |
Dec 31, 2022 | 58 | 15 | 34.88% |
Dec 31, 2021 | 43 | 20 | 86.96% |
Dec 31, 2020 | 23 | - | - |
Related Stocks
Company Name | Employees |
---|---|
DocGo | 4,164 |
Zynex | 1,100 |
Aurora Cannabis | 1,073 |
Spok Holdings | 384 |
Amarin Corporation | 275 |
Nyxoah | 147 |
Foghorn Therapeutics | 116 |
Scilex Holding Company | 105 |
ALXO News
- 7 weeks ago - ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder Cancer - GlobeNewsWire
- 7 weeks ago - ALX Oncology Announces Participation in the Jefferies Global Healthcare Conference - GlobeNewsWire
- 2 months ago - ALX Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 2 months ago - ALX Oncology Appoints Allison Dillon as Chief Business Officer - GlobeNewsWire
- 3 months ago - ALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual Meeting - GlobeNewsWire
- 3 months ago - ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (“R/R B-NHL”) - GlobeNewsWire
- 4 months ago - ALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update - GlobeNewsWire
- 4 months ago - ALX Oncology Announces Two Evorpacept Clinical Abstracts Accepted for Presentation at the AACR Annual Meeting - GlobeNewsWire